These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 17229638)
1. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Marijt E; Wafelman A; van der Hoorn M; van Bergen C; Bongaerts R; van Luxemburg-Heijs S; van den Muijsenberg J; Wolbers JO; van der Werff N; Willemze R; Falkenburg F Haematologica; 2007 Jan; 92(1):72-80. PubMed ID: 17229638 [TBL] [Abstract][Full Text] [Related]
2. Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. Falkenburg JH; Faber LM; van den Elshout M; van Luxemburg-Heijs SA; Hooftman-den Otter A; Smit WM; Voogt PJ; Willemze R J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):305-9. PubMed ID: 8280712 [TBL] [Abstract][Full Text] [Related]
3. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Falkenburg JH; Wafelman AR; Joosten P; Smit WM; van Bergen CA; Bongaerts R; Lurvink E; van der Hoorn M; Kluck P; Landegent JE; Kluin-Nelemans HC; Fibbe WE; Willemze R Blood; 1999 Aug; 94(4):1201-8. PubMed ID: 10438707 [TBL] [Abstract][Full Text] [Related]
4. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation. Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939 [TBL] [Abstract][Full Text] [Related]
5. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells. Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594 [TBL] [Abstract][Full Text] [Related]
6. Production of donor-derived cytotoxic T lymphocytes with potent anti-leukemia activity for adoptive immunotherapy in high-risk pediatric patients given haploidentical hematopoietic stem cell transplantation. Tanzi M; Montini E; Rumolo A; Moretta A; Comoli P; Acquafredda G; Rotella J; Taurino G; Compagno F; Cave FD; Perotti C; Marseglia GL; Zecca M; Montagna D Cytotherapy; 2024 Aug; 26(8):878-889. PubMed ID: 38703155 [TBL] [Abstract][Full Text] [Related]
7. Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation. Montagna D; Maccario R; Locatelli F Int J Immunogenet; 2008 Aug; 35(4-5):389-93. PubMed ID: 18976444 [TBL] [Abstract][Full Text] [Related]
8. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors. Montagna D; Maccario R; Montini E; Tonelli R; Lisini D; Pagani S; Comoli P; Moretta A; Assirelli E; Basso S; Vitiello A; Pession A; Locatelli F Exp Hematol; 2003 Nov; 31(11):1031-8. PubMed ID: 14585366 [TBL] [Abstract][Full Text] [Related]
9. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. Faber LM; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH J Exp Med; 1992 Nov; 176(5):1283-9. PubMed ID: 1402674 [TBL] [Abstract][Full Text] [Related]
10. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon. Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352 [TBL] [Abstract][Full Text] [Related]
11. Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation. Hoogendoorn M; Olde Wolbers J; Smit WM; Schaafsma MR; Jedema I; Barge RM; Willemze R; Falkenburg JH Clin Cancer Res; 2005 Jul; 11(14):5310-8. PubMed ID: 16033850 [TBL] [Abstract][Full Text] [Related]
12. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791 [TBL] [Abstract][Full Text] [Related]
13. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. Kurokawa T; Fischer K; Bertz H; Hoegerle S; Finke J; Mackensen A Int J Cancer; 2002 Sep; 101(1):52-60. PubMed ID: 12209588 [TBL] [Abstract][Full Text] [Related]
19. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; Ochsenreither S; Wölfl M; Bar M; Radich JP; Yee C; Greenberg PD Sci Transl Med; 2013 Feb; 5(174):174ra27. PubMed ID: 23447018 [TBL] [Abstract][Full Text] [Related]
20. [The success of lymphocyte infusion as treatment of leukemia recurrence following allogeneic bone marrow transplantation depends on low percentage of patient's own lymphocytes]. Schattenberg AV; van de Wiel-van Kemenade E; Bär BM; Geurts van Kessel AH; van der Maazen RW; de Witte TJ Ned Tijdschr Geneeskd; 1996 Oct; 140(42):2087-91. PubMed ID: 8965951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]